Gary S. Jacob

CIK: 0001266802

Transaction Breakdown

Open Market Buys (P)1 (50.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

OKYO

OKYO Pharma Ltd

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (2 total)

OKYO
OKYO Pharma Ltd
Jul 21, 2026
Purchase(P)
Direct
3.5K shares at avg. $1.40$5K
OKYO
OKYO Pharma Ltd
Jul 21, 2026
Award(A)
Direct
3.5K shares at avg. $1.40$5K

		Type	Shares	Price		Ownership
Jul 21, 2026	OKYO OKYO Pharma Ltd	Purchase(P)	3,500	$1.40	$4,900	Direct
Jul 21, 2026	OKYO OKYO Pharma Ltd	Award(A)	3,500	$1.40	$4,900	Direct

1-2 of 2 transactions

About JACOB GARY S

JACOB GARY S (SEC CIK 0001266802) files insider reports with the SEC as CHIEF DEVELOPMENT OFFICER of OKYO Pharma Ltd (OKYO).

Signal8 holds 3 ownership filings by JACOB GARY S (1 Form 3, 2 Form 4), filed between Mar 18, 2026 and Aug 7, 2026. Those filings report 2 transactions, the latest on Jul 21, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on JACOB GARY S's filings is in LONDON.

Recent filings by JACOB GARY S

Jul 21, 2026: Open-market purchase of OKYO shares (Form 4, code P).
Jul 21, 2026: Grant or award of OKYO shares (Form 4, code A).

Other insiders filing for OKYO Pharma Ltd (OKYO)

BRANCACCIO JOHN P, Director
Dempsey Robert John, CHIEF EXECUTIVE OFFICER
CERRONE GABRIELE M, Director
Mantelli Flavio, CHIEF MEDICAL OFFICER
Patil Rajkumar V., Chief Scientific Officer
Denoyer Bernard, Director

How to read Form 4 transaction codes